• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌的分类和分期:辅助临床决策。

Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making.

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA.

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA.

出版信息

Clin Liver Dis. 2015 May;19(2):277-94. doi: 10.1016/j.cld.2015.01.011.

DOI:10.1016/j.cld.2015.01.011
PMID:25921663
Abstract

Classification and staging of hepatocellular carcinoma in a way that allows optimal treatment selection is challenging. This article summarizes some of the classification and staging schemes and discusses the conceptual framework that guides optimal treatment selection for each patient. The article does not exhaustively discuss each staging system proposed in the last three decades, but rather reviews the most commonly used staging systems, evaluates the rationale behind some of the newer staging systems, and compares them focusing on their use in clinical decision-making, notably choice of therapy.

摘要

以能够优化治疗选择的方式对肝细胞癌进行分类和分期极具挑战性。本文总结了一些分类和分期方案,并讨论了指导每位患者最佳治疗选择的概念框架。本文没有详尽地讨论过去三十年中提出的每一个分期系统,而是回顾了最常用的分期系统,评估了一些新分期系统背后的基本原理,并对它们进行了比较,重点是它们在临床决策中的应用,特别是治疗选择。

相似文献

1
Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making.肝细胞癌的分类和分期:辅助临床决策。
Clin Liver Dis. 2015 May;19(2):277-94. doi: 10.1016/j.cld.2015.01.011.
2
Management of hepatocellular carcinoma.肝细胞癌的管理
Clin Liver Dis. 2007 May;11(2):305-21. doi: 10.1016/j.cld.2007.04.007.
3
Liver tumors and loco-regional therapy.肝脏肿瘤与局部区域治疗。
Wien Med Wochenschr. 2013 Mar;163(5-6):107-8. doi: 10.1007/s10354-013-0188-2.
4
Downstaging hepatocellular carcinoma prior to liver transplantation.肝移植前降低肝细胞癌分期
Liver Transpl. 2005 Dec;11(12):1466-8. doi: 10.1002/lt.20528.
5
[Resection or interventional treatment of hepatocellular carcinoma: which method for which patient?].[肝细胞癌的切除术或介入治疗:哪种方法适用于哪种患者?]
Dtsch Med Wochenschr. 2013 Sep;138(36):1780-4. doi: 10.1055/s-0033-1343347. Epub 2013 Aug 13.
6
Hepatocellular carcinoma: MR staging and therapeutic decisions.肝细胞癌:磁共振成像分期与治疗决策
Abdom Imaging. 2012 Apr;37(2):231-8. doi: 10.1007/s00261-011-9735-8.
7
Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon.二级医院肝细胞癌的多学科治疗方法:阿尔科孔大学基金会医院的首个十年
Hepatogastroenterology. 2015 Jun;62(140):971-7.
8
Management of Hepatocellular Carcinoma: Current Status and Future Directions.肝细胞癌的管理:现状与未来方向。
Gut Liver. 2015 Jul;9(4):437-48. doi: 10.5009/gnl15022.
9
Staging systems for hepatocellular carcinoma: should we all use the BCLC system?肝细胞癌的分期系统:我们都应该使用巴塞罗那临床肝癌(BCLC)系统吗?
J Hepatol. 2006 Apr;44(4):630-2. doi: 10.1016/j.jhep.2006.02.003. Epub 2006 Feb 17.
10
Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective.巴塞罗那临床肝癌分类中肝细胞癌的灰色地带:外科医生的观点。
World J Gastroenterol. 2015 Jul 21;21(27):8256-61. doi: 10.3748/wjg.v21.i27.8256.

引用本文的文献

1
Prostate-specific membrane antigen-targeting radiopharmaceuticals: a new frontier in hepatic malignancies.前列腺特异性膜抗原靶向放射性药物:肝脏恶性肿瘤治疗的新前沿
Front Oncol. 2025 Mar 7;15:1547459. doi: 10.3389/fonc.2025.1547459. eCollection 2025.
2
SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023).SEOM-GEMCAD-TTD 肝癌患者管理临床指南(2023 年)。
Clin Transl Oncol. 2024 Nov;26(11):2800-2811. doi: 10.1007/s12094-024-03568-4. Epub 2024 Jun 24.
3
Feasibility Study of Computed Tomographic Radiomics Model for the Prediction of Early and Intermediate Stage Hepatocellular Carcinoma Using BCLC Staging.
基于BCLC分期的计算机断层扫描影像组学模型预测早期和中期肝细胞癌的可行性研究
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241245943. doi: 10.1177/15330338241245943.
4
Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma.用于肝细胞癌成像的正电子发射断层显像(PET)放射性药物的最新进展
Cancers (Basel). 2023 Mar 25;15(7):1975. doi: 10.3390/cancers15071975.
5
Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography-Mass Spectrometry-Based Metabolomics.基于气相色谱-质谱联用代谢组学研究肝细胞癌的代谢重编程与风险分层
Cancers (Basel). 2022 Jan 4;14(1):231. doi: 10.3390/cancers14010231.
6
A Powerful Nomogram Based on the Novel D-Index to Predict Prognosis After Surgical Resection of Hepatocellular Carcinoma.基于新型D指数的强大列线图预测肝细胞癌手术切除后的预后
Cancer Manag Res. 2021 Mar 17;13:2581-2594. doi: 10.2147/CMAR.S305253. eCollection 2021.
7
Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment.白蛋白-胆红素指数和血小板-白蛋白-胆红素指数有助于识别接受索拉非尼治疗的经动脉化疗栓塞术的肝细胞癌和Child-Pugh A级患者中的生存获益候选者。
Ann Transl Med. 2021 Feb;9(3):237. doi: 10.21037/atm-20-3118.
8
Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database.I期肝细胞癌患者的管理与生存:一项基于监测、流行病学和最终结果(SEER)数据库的观察性研究。
Medicine (Baltimore). 2020 Oct 9;99(41):e22118. doi: 10.1097/MD.0000000000022118.
9
Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma.钆塞酸二钠增强磁共振成像在肝细胞癌中的应用。
World J Surg Oncol. 2020 Aug 22;18(1):219. doi: 10.1186/s12957-020-01996-4.
10
Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection.建立基因组-临床病理列线图预测 R0 切除后肝细胞癌早期复发。
J Gastrointest Surg. 2021 Jan;25(1):112-124. doi: 10.1007/s11605-020-04554-1. Epub 2020 Mar 3.